28 Biotech Stocks Where Funds, Insiders, and Catalysts All Agree

The signal score (0-200) is a weighted composite of five independent data sources: fund convergence (how many specialist hedge funds hold the stock), insider buying (Form 4 open market purchases), catalyst proximity (days until FDA decision or data readout), short interest (contrarian pressure), and cash runway safety (dilution risk). Each component contributes points, and higher scores mean more signals are aligning.

Fund convergence measures how many specialist biotech hedge funds independently hold the same stock. When 3 or more concentrated portfolio managers — like Baker Brothers, Perceptive, or RA Capital — all build positions in one company, it signals strong institutional conviction. These aren't index funds; they're active stock pickers doing deep due diligence.

Individual signals can be noisy — a single insider buy or one fund holding doesn't tell you much. But when a stock has multiple funds buying, an insider purchase, and an approaching catalyst, the probability of each signal being noise drops dramatically. The composite score surfaces stocks where independent signals are converging.